2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. by Hickish, T. et al.
Br. J. Cancer (1993), 67, 139 143 1993
2'-Chlorodeoxyadenosine: evaluation of a novel predominantly
lymphocyte selective agent in lymphoid malignancies
T. Hickishl, P. Serafinowski2, D. Cunningham', A. Oza3, E. Dorland2, I. Judson' 2, B.C. Millar',
T.A. Lister3 & A. Roldan'
'Section ofMedicine, 2Section ofDrug Development, Institute ofCancer Research, Royal Marsden Hospital, Sutton, Surrey;
'Department ofMedical Oncology, St. Bartholomew's Hospital, London, UK.
Summary 2'-Chlorodeoxyadenosine (2CDA) is a purine analogue selectively active against both resting and
dividing lymphoid cells. Twenty-one patients with a variety of previously treated lymphoid malignancies
received a total of 41 courses of 2CDA (0.1-0.15 mg/kg/day over 7 days continuous intravenous infusion) on
compassionate grounds. The profile of the patient population was as follows: low grade non-Hodgkin's
lymphoma (NHL) = 8, intermediate grade NHL = 2, transformed (intermediate grade NHL)
= 6, Hodgkin's
disease = 1, lymphoplasmacytoid NHL = 3 and lymphoblastic NHL = 1. The overall response rate was 53%,
with three patients attaining complete remission (CR) and eight partial remission (PR). Three of 16 patients
with primary resistant or resistant recurrent disease entered either CR (1) or PR (2). Ten patients had no
response or progressive disease. The latter group was comprised of patients who had extensively pre-treated
lymphoplasmacytoid tumours and/or poor performance status (WHO grades 2-4). The median duration of
response is 6 months (range I to 12 months). Treatment was well tolerated and the chief toxicities were
leucopenia and thrombocytopenia which were most pronounced when there was bone marrow involvement. As
a result of dose limiting myelotoxicity, a dose escalation to 0.15 mg/kg/day was possible on just three
occasions.
These data confirm other reports of the activity of 2CDA in low grade NHL and indicate it may have
activity in Hodgkin's disease. There was no demonstrable activity in poor performance status patients or those
with extensively pre-treated lymphoplasmacytoid tumours.
2'-Chlorodeoxyadenosine (2CDA) has cytotoxic activity both
in resting and dividing cells. Its mechanism of action requires
phosphorylation by deoxycytidine kinase and since in the
main this enzyme is expressed in lymphocytes, 2CDA has the
virtue of primarily being active in lymphoid tissue (Carson et
al., 1983). The phosphorylated derivative of 2CDA (CdATP)
inhibits ribonucleotide reductase and hence depletes the in-
tracellular pool of deoxynucleotides (Avery et al., 1989). In
actively dividing cells DNA synthesis is impaired and this
effect is compound by preferential use of CdATP by DNA
polymerase with subsequent retardation of chain elongation
(Chunduru & Blakley, 1991). The cytopathic mechanism in
resting cells may be by induction of programmed cell death
since DNA degradation in chronic lymphocytic leukaemia
cells incubated with 2CDA is typical of apoptosis (Robertson
et al., 1991). The crucial step is thought to be a reduction in
NAD. NAD is essential for energy production and its defici-
ency results in cell death. This may result from the perturba-
tion of the deoxynucleotide pool to produce defective repair
of angle-strand breaks in DNA with resultant activation of
poly (ADP - ribose) polymerase and consequent consump-
tion of NAD. In vitro, the cytotoxic effect of 2CDA can be
prevented by restoring the lost NAD by culture with nico-
tinamide despite the occurrence of strand breaks in DNA
(Seto et al., 1985). Other processes may be involved in the
action of 2CDA since in vitro it inhibits the growth of
myeloid progenitor cells in which the levels of deoxycytidine
kinase are low (Petzer et al., 1992). Similarly it has activity in
acute myeloid leukaemia (Santana et al., 1992) and the main
toxicity encountered in clinical trials has been myelosuppres-
sion.
A number of phase I and phase I/II studies have investi-
gated the activity of 2CDA in white cell malignancies, the
majority having been initiated by the Scripps clinic (Piro,
L.D., 1992; Piro et al., 1990; Beutler et al., 1991; Piro et al.,
1988; Kahn et al., 1991; Kay et al., 1992). These have shown
that 2CDA has promising activity in lymphoid and myeloid
malignancies of both high and low grade types. In a recent
study, 24 children with refractory leukaemia received 2CDA
at 8.9 mg/m2/day over 5 days. Forty-seven per cent of pati-
ents with AML achieved a complete remission with two
(12%) achieving partial remission. Only one of seven patients
with ALL achieved CR (Santana et al., 1992).
Of the low grade leukaemias excellent activity has been
found in hairy cell leukaemia (HCL) with 32 of 45 patients
achieving complete remission after a single course of 0.1 mg/
kg/day for 7 days (Piro et al., 1990; Beutler et al., 1991). No
patient has relapsed and 2CDA seems likely to become the
treatment of choice in this disease. In patients with chronic
lymphocytic leukaemia (CLL) who received repeated courses
of 0.1 mg/kg/day over 7 days, 38 of 89 patients attained a
partial remission, with just three patients entering complete
remission (Beutler et al., 1991).
The group from the Scripps clinic have also recently de-
scribed their experience of repeated courses of 2CDA
(0.1 mg/kg/day over 7 days) in 40 patients with refractory
low grade and transformed low grade non-Hodgkin's lym-
phoma (Kay et al., 1992). Eight (20%) of patients achieved
CR and nine (22.5%) PR. The duration of response ranged
from I to over 33 months.
Over the past 20 months we have treated 21 patients on
compassionate grounds for a variety of lymphoid tumours
with 2CDA synthesised in our laboratories.
Materials and methods
To be eligible for treatment patients required a histologically
confirmed diagnosis with evaluable disease and who had been
previously treated with conventional agents (and in a number
of cases; investigational agents). Eight patients had low grade
NHL, two intermediate grade NHL, six transformed to inter-
mediate grade NHL, three lymphoplasmacytoid lymphoma,
one lymphoblastic NHL and one patient had nodular scler-
osing Hodgkin's disease. Details of patients age, sex, his-
tology, stage of disease and previous treatment are shown in
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Table I. Treatment was offered on compassionate grounds
and patients gave informed consent.
Synthesis andpurification
The methodology for 2CDA was based on the condensation
of 2,6-dichloropurine and 2-deoxy-3,5-bis-O-(4-methylben-
zoyl)-a-D erythropentofuanosyl chloride under solid liquid
phase transfer conditions. This methodology enables more
efficient and safer synthesis and is suitable for large scale
production (Seela & Boureois, 1989; Soula, 1985).
The drug was supplied as a sterile solution at a concentra-
tion of 2 mg ml-' in 0.9% NaCl.
Drug administration
The required amount of 2CDA was added to 500 ml 0.9%
NaCl and infused via a 0.2 gm filter intravenously over 24 h.
This was repeated daily for 7 days. Courses were given in 28
day cycles.
Response evaluation
Disease was evaluated according to the WHO guidelines
(Miller et al., 1981) and assessment included CT scanning,
ultrasound and a bone marrow aspirate and trephine. Pa-
tients received further courses (to a maximum of four) if
there was evidence of at least a partial response. The starting
dose was 0.1 mg/kg/day over 7 days and this was increased
to 0.15 mg/kg/day over 7 days if the platelet and white blood
cell count were respectively > 100,000 x 091-' and
>IOOOxlO091-'.
Toxicity monitoring
Toxicity was recorded according to the WHO criteria (Miller
et al., 1981) and toxicities are shown in Table I. A full blood
count was measured at least weekly between courses.
Results
Twenty-one patients received a total of 41 courses of 2CDA.
Responses
Responses are recorded in Table I and summarised in Table II
Duration of response Eleven patients responded to treatment
with 2CDA. The median duration of response is 6 months
(range; 1 to 12 months). Two of the three patients who
attained CR remain disease free after 12 months. One patient
died in PR 8 months after treatment with no evidence of
progressive disease and one patient in PR died of a neutro-
penic sepsis. The patient with Hodgkin's disease relapsed 6
months after treatment. The one case of lymphoblastic NHL
(second relapse) attained a partial response which endured
over three cycles of treatment.
Treatment failures Ten patients had no response to treat-
ment. One patient had a low grade NHL which had responded
to the first course of 2CDA but transformed to an inter-
mediate grade NHL during a second course. Four out of six
patients with transformed NHL failed to respond. Three
patients with lymphoplasmacytoid lymphomas failed to re-
spond. All three had been extensively pre treated including
treatment with fludarabine. This drug has a similar mechan-
ism of action to 2CDA and all three had failed to respond to
this agent. Similarly, two patients with follicular low grade
NHL, one of which secreted a paraprotein, had both received
fludarabine and failed to respond. Six out of seven patients
with poor performance status (WHO 2-4) failed to respond.
Toxicity The primary toxicity was myelosuppression with
both leucopenia and thrombocytopenia (Tables I and III). As
a result of dose limiting myelotoxicity a dose escalation (to
0.15 mg/kg/day over 7 days) was made on only three
occasions. Three patients had thrombophlebitis. The five
patients who had bone marrow failure prior to treatment
could not be evaluated for myelotoxicity. Three patients were
not evaluable for toxicity either due to death or the imple-
mentation of further treatment. All four patients who had
bone marrow involvement and who were evaluable for toxi-
city have had continuing myelosuppression (WHO grade 1-2
thrombocytopenia; WHO grade 1-3 leucopenia) up to 8
Inonths after treatment (Table I).
Discussion
In this series of patients it has been shown that 2CDA
(0.1 mg/kg/day over 7 days (has significant anti tumour
activity in pre-treated low grade NHL and in the one case of
Hodgkin's disease studied. The group of patients in whom
2CDA was ineffective comprised those with lymphoplasmacy-
toid and transformed lymphomas, and/or poor performance
status. The lack of response of the lymphoplasmacytoid lym-
phomas may in part be due to their previous treatment.
These patients plus another patient with follicular low grade
NHL had all previously failed to respond to fludarabine.
Table II Response to 2-chlorodeoxyadenosine
Relapse Resistant relapse Primary resistant
CR PR NC/PD CR PR NC/PD CR PR NC/PD
Low grade 2 1 1 2 2
Intermediate grade 1 1
Transformed NHL 2 4
Hodgkin's lymphoma 1
Lymphoplasmacytoid 3
Lymphoblastic 1
Table III Maximum myelotoxicity of 2CDA (13 evaluable patients)
WHO grade
0 1-2 3-4
Patients with
BM involvement Leucopenia 2 (22%) 7 (78%)
= 9 Thrombocytopenia 5 (55%) 4 (45%)
Patients with
normal BM Leucopenia 2 (40%) 2 (40%) 1 (20%)
=4 Thrombocytopenia 1 (20%) 3 (60%) 1 (20%)2CDA FOR LYMPHOID MALIGNANCIES 143
Fludarabine has a similar mechanism of action to 2CDA and
requires phosphorylation by deoxycytidine kinase to F-ara-
ATP for activation (Plunket et al., 1990) and is associated
with the induction of apoptosis (Robertson et al., 1991).
Fludarabine has been reported to have a higher ID50 than
2CDA against a number of cell lines indicating it may be a
less active drug (Carson et al., 1980). Therefore lymphoplas-
macytoid tumours may be relatively resistant to 2CDA (and
fludarabine). Currently we are investigating the possibility
that resistance in this group of malignancies is related to a
low level of deoxycytidine kinase expression.
In accord with other studies toxicity was chiefly limited to
thrombocytopenia and leucopenia. One case of fatal neutro-
penic sepsis occurred within 28 days as receiving 2CDA. This
occurred in a patient with an aggressive transformed non-
Hodgkin's lymphoma associated with extensive bone marrow
infiltration and bone marrow failure. He had had a partial
response to one course of 2CDA. Of the patients evaluable
for toxicity, four had histologically detectable bone marrow
infiltration and have had continuing myelosuppression up to
seven months after treatment with three courses of 2CDA.
Whatever its mechanism of action, 2CDA has a marked
impact on the myeloid compartment and this has led one
group to propose that it may have a role as a conditioning
regimen in the setting of allogeneic bone marrow transplanta-
tion in acute leukaemia (Santana et al., 1991).
The optimum dosing and dose schedule has probably not
yet been reached. A regimen based on continuous infusion
may not be necessary since pharmacokinetic studies have
shown that after a daily 2 h infusion of 2CDA (0.14 mgkg-'
times 5 days), the terminal elimination phase is prolonged
with a plasma half-life of 6 h and a similar area under the
concentration vs time curve when compared to a continuous
intravenous infusion schedule (Liliemark & Juliusson, 1991,
Liliemark & Juliusson, 1992). Furthermore, the T/2 of 2CDA
and its phosphorylated metabolites in leukaemia cells from
patients with CLL and HCL is approximately 24 h, and
similar for both intermittent and continuous schedules
(Liliemark & Juliusson, 1992). However different conditions
may apply in different tumour types as in vitro studies have
demonstrated rapid clearance of 2CDA and its metabolites
from lymphoid and myeloid cell lines (Avery et al., 1989).
Oral administration of 2CDA is feasible, with a bio-
availability of 20-70%, and is therefore potentially major
therapeutic significance (Liliemark & Juliusson, 1992).
A partial response was attained in the one case of Hodg-
kin's disease studied and therefore 2CDA merits further
investigation in this malignancy.
2CDA is associated with minimal non myelosuppressive
toxicity and is active in extensively pre treated low grade
NHL. Therefore, either singly or in combination, it
represents a novel option as a salvage therapy and merits
evaluation as a front line agent in this tumour.
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